Mohammad Karamouzian

Mohammad Karamouzian

Auto-generated profile, based on publicly available information

Mohammad Karamouzian

Centre on Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael’s Hospital, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2021 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
ASAkash Sharma Akash Sharma
Akash Sharma Akash Sharma
MTMinh Duc Nguyen Tran
Minh Duc Nguyen Tran
TTTai Luu Lam Thang
Tai Luu Lam Thang
NNNguyen Hai Nam
Nguyen Hai Nam
SNSze Jia Ng
Sze Jia Ng
MKMohammad Karamouzian
Mohammad Karamouzian

5 September 2017 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
MKMary Clare Kennedy
Mary Clare Kennedy
MKMohammad Karamouzian
Mohammad Karamouzian
TKThomas Kerr
Thomas Kerr

2 July 2016 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
PSProf. Dr. Benedikt Schoser
Prof. Dr. Benedikt Schoser
ASAndrew Stewart
Andrew Stewart
SKSteve Kanters
Steve Kanters
AHAlaa Hamed
Alaa Hamed
JJJeroen Jansen
Jeroen Jansen
ATAntonio Toscano
Antonio Toscano

15 August 2017 in Substance Abuse Treatment, Prevention, and Policy
Verified
Journal Article
Open access
PDF file
PVPauline Voon
Pauline Voon
MKMohammad Karamouzian
Mohammad Karamouzian
TKThomas Kerr
Thomas Kerr
The crisis of prescription opioid (PO) related harms has focused attention toward identifying and treating high-risk populations. This review aims to synthesize systematic reviews on the epidemiology and clinical management of comorbid chronic pain and PO or other substance misuse. A systematic database search was conducted to identify systematic reviews published between 2000 and 2016. Eligible studies were systematic reviews related to chronic non-cancer pain and PO or other substance misuse. Evidence from the included reviews was synthesized according to epidemiology and clinical management themes. Of 1908 identified articles, 18 systematic reviews were eligible for final inclusion. Two meta-analyses estimated the prevalence of chronic non-cancer pain in individuals using POs non-medically to be approximately 48% to 60%, which is substantially higher than the prevalence of chronic non-cancer pain in general population samples (11% to 19%). Five systematic reviews estimated the rates of PO or other opioid use in chronic pain populations with substantial variation in results (0.05% to 81%), likely due to widely varying definitions of dependence, substance use disorder, misuse, addiction, and abuse. Several clinical assessment and treatment approaches were identified, including: standardized assessment instruments; urine drug testing; medication counts; prescription drug monitoring programs; blood level monitoring; treatment agreements; opioid selection; dosing and dispensing strategies; and opioid agonist treatment. However, the reviews commonly noted serious limitations, inconsistencies, and imprecision of studies, and a lack of evidence on effectiveness or clinical utility for the majority of these strategies. Overall, current systematic reviews have found a lack of high-quality evidence or consistent findings on the prevalence, risk factors, and optimal clinical assessment and treatment approaches related to concurrent chronic pain and substance misuse. Given the role of systematic reviews in guiding evidence-based medicine and health policy, there is an urgent need for high-quality primary research to guide future systematic reviews to address the escalating epidemic of harms related to chronic pain and substance misuse.

10 September 2018 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
MKMohammad Karamouzian
Mohammad Karamouzian
CDCarolyn Dohoo
Carolyn Dohoo
SFSara Forsting
Sara Forsting
RMRyan McNeil
Ryan McNeil
TKThomas Kerr
Thomas Kerr
MLMark Lysyshyn
Mark Lysyshyn
British Columbia, Canada, is experiencing a public health emergency related to opioid overdoses driven by consumption of street drugs contaminated with illicitly manufactured fentanyl. This cross-sectional study evaluates a drug checking intervention for the clients of a supervised injection facility (SIF) in Vancouver. Insite is a facility offering supervised injection services in Vancouver’s Downtown East Side, a community with high levels of injection drug use and associated harms, including overdose deaths. During July 7, 2016, to June 21, 2017, Insite clients were offered an opportunity to check their drugs for fentanyl using a test strip designed to test urine for fentanyl. Results of the drug check were recorded along with information including the substance checked, whether the client intended to dispose of the drug or reduce the dose and whether they experienced an overdose. Logistic regression models were constructed to assess the associations between drug checking results and dose reduction or drug disposal. Crude odds ratios (OR) and 95% confidence intervals (CI) were reported. About 1% of the visits to Insite during the study resulted in a drug check. Out of 1411 drug checks conducted by clients, 1121 (79.8%) were positive for fentanyl. Although most tests were conducted post-consumption, following a positive pre-consumption drug check, 36.3% (n = 142) of participants reported planning to reduce their drug dose while only 11.4% (n = 50) planned to dispose of their drug. While the odds of intended dose reduction among those with a positive drug check was significantly higher than those with a negative result (OR = 9.36; 95% CI 4.25–20.65), no association was observed between drug check results and intended drug disposal (OR = 1.60; 95% CI 0.79–3.26). Among all participants, intended dose reduction was associated with significantly lower odds of overdose (OR = 0.41; 95% CI 0.18–0.89). Although only a small proportion of visits resulted in a drug check, a high proportion (~ 80%) of the drugs checked were contaminated with fentanyl. Drug checking at harm reduction facilities such as SIFs might be a feasible intervention that could contribute to preventing overdoses in the context of the current overdose emergency.

14 September 2013 in Sexually Transmitted Infections
Verified
Journal Article
Open access
PDF file
RKRazieh Khajehkazemi
Razieh Khajehkazemi
MOMehdi Osooli
Mehdi Osooli
LSLeily Sajadi
Leily Sajadi
MKMohammad Karamouzian
Mohammad Karamouzian
ASAbbas Sedaghat
Abbas Sedaghat
AHAliakbar Haghdoost
Aliakbar Haghdoost
Objectives To assess the prevalence of HIV and related risk behaviours among people who inject drugs (PWID) in Iran. Methods We conducted a national cross-sectional bio-behavioural surveillance survey between March and July 2010, interviewing male PWID from a geographically dispersed sample through a facility-based sampling method. Results We recruited 2480, and tested 2290 PWID. The overall prevalence of HIV was 15.2% (95% CI 9.7% to 23.1%). Among those who had injected drugs over the last month, 36.9% had used a non-sterile needle, and 12.6% had practiced shared injection. Over the past 12 months preceding the interview, 30.4% had sold sex for money, drugs, goods or a favour. In the multivariate analysis, the prevalence of HIV had a positive association with age, while having above high school education, and permanent job were protective. Conclusions Unsafe injection, and sexual risk behaviours are still frequent and the prevalence of HIV among PWID remains high. Intensified efforts are needed to prevent the further spread of HIV among Iranian PWID and their sexual partners.